Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adaptimmune Therapeutics PLC

0.2653
-0.0013-0.49%
Post-market: 0.27550.0102+3.84%19:34 EDT
Volume:474.18K
Turnover:128.79K
Market Cap:68.24M
PE:-0.88
High:0.2840
Open:0.2840
Low:0.2608
Close:0.2666
Loading ...

Company Profile

Company Name:
Adaptimmune Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
506
Office Location:
60 Jubilee Avenue,Milton Park,Abingdon,Oxfordshire,United Kingdom
Zip Code:
OX14 4RX
Fax:
- -
Introduction:
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Directors

Name
Position
David M. Mott
Chairman and Director
James Noble
Chief Executive Officer and Director
Ali Behbahani
Director
Barbara Duncan
Director
Elliott Sigal
Director
Giles Kerr
Director
Lawrence M. Alleva
Director
Peter Thompson
Director
Tal Zaks
Director

Shareholders

Name
Position
James Noble
Chief Executive Officer and Director
William Bertrand
Chief Operating Officer
Adrian Rawcliffe
Chief Financial Officer
Gwendolyn Binder Scholl
Chief Technology Officer
Helen Tayton Martin
Chief Business Officer
Rafael Amado
Chief Medical Officer